Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Ocugen, Inc (OCGN)

NASDAQ
Currency in USD
Disclaimer
1.640
-0.140(-7.87%)
Closed
After Hours
1.6400.000(0.00%)

OCGN Price Commentary

take off imminent
w,h,o approval next week until buy hold
are you sure?
yes 26 October, w ,h,o approval hopefully
buy ocgn don't miss the train
where is the end? Will it be 12 or higher again?
hopefully 12
will open up usa session
approved for kids 2-18
https://twitter.com/IndiaToday/status/1447836764463271939?t=9OE3NxhGKlWAjqnn-8F5LA&s=19
next week approval coming, to the moon ,don't miss the chance
WHO approval next week, date confirmed
Was Expertenmeinung: Experten rechnen damit, dass das Unternehmen schon bald eine Zulassung von der WHO erhalten dürfte. Sollte dies passieren, könnten die Kurse durch die Decke gehen. Gleichzeitig wäre eine Nichtzulassung natürlich ein Grund für einen Absturz der Aktie. Hier dürfte selbst ein guter Stopp unter der Marke von 7 USD nichts helfen. Es ist eine Art Lotterieschein, doch durchaus einer mit Potential, denn die Chance nach oben ist wohl um ein Vielfaches höher als das Risiko nach unten, welches bekanntlich 100% beträgt. Vielleicht also ein gutes Investment mit entsprechend kleinem Risikokapital Sie über Ocugen, Inc
buy ocgn next target 12 dollar
When?
till December
last call, all aboard the money train
https://stockstees.myshopify.com/collections/ocgn-x-bb 1 shirt 1 share
ocugen sending doses to India eh
https://ipolitics.ca/2021/07/15/health-canada-considers-approving-covaxin-vaccine/
Technical analysis is totally useless here.. Ocugen is all about the news. If the news is positive it flies. If its negative it drops like a ton of bricks.
@Aaron, what data please?
I think he may be referring to the Afterhours 13.7% rise in stock and general bullish trending line over the past 12 days. But that's just a guess any more data analyses is always appreciated.
Results from phase 3 has just come showing good efficacy. Against covid 19 including the delta variant. That caused the spike outside trading hours.
 Thank you James good to have good news.
data released bullish
https://www.nih.gov/news-events/news-releases/adjuvant-developed-nih-funding-enhances-efficacy-indias-covid-19-vaccine
This is an incredibly dangerous play so many variables can shift the share price. Sensible move is not to invest more than 2.5% to 5% of your portfolio in this stock. Not financial advice, just my opinion.
let's see how this plays out
news
The news we was hoping for! Lets go! Time to shiiiine!
We are back on track, as today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN™ to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets
the worst stock that I had been followed. from 13 to 6...
fda not approved in US
fda recommended they seek BLA.
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.